Caspofungin
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Caspofungin: From Invasive Fungal Infections to Gastrin Secretion Abnormality
One-Sentence Summary
Caspofungin is an echinocandin antifungal marketed in the US for invasive fungal infections. The TxGNN model predicts it may be relevant to gastrin secretion abnormality, but this rests on the model score alone, with 0 clinical trials and 0 publications supporting it. No credible mechanistic link has been identified, so this is a low-confidence prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Invasive fungal infections (not stated in the license records; taken from drug class knowledge) |
| Predicted New Indication | Gastrin secretion abnormality |
| TxGNN Prediction Score | 99.44% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 14 (the listed records are ANDA generics) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the source record. Caspofungin is an echinocandin antifungal that inhibits fungal beta-(1,3)-D-glucan synthase, an enzyme that mammalian cells do not have.
No known pathway connects this mechanism to gastrin regulation, G-cell function, or gastric acid secretion. The original indication (fungal infection) and the predicted indication (a gastrin regulation disorder) also have no apparent biological relationship.
The score of 99.44% (rank 12,995) comes from knowledge-graph patterns only. A high score alone should not be read as a sign of real efficacy. At this stage the prediction is a hypothesis to test, not a reasonable repurposing candidate.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ANDA207092 | Caspofungin Acetate (Fosun Pharma USA Inc.) | Lyophilized powder for injection | Not provided in the record |
| ANDA207092 | Caspofungin Acetate (Sagent Pharmaceuticals) | Lyophilized powder for injection | Not provided in the record |
| ANDA200833 | Caspofungin Acetate (Sandoz Inc) | Lyophilized powder for injection | Not provided in the record |
| ANDA207092 | Caspofungin Acetate (Gland Pharma Limited) | Lyophilized powder for injection | Not provided in the record |
Safety Considerations
- Drug Interactions: No interaction records were found in the queried database.
Please refer to the package insert for other safety information, including warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical or literature support (L5), and the known antifungal mechanism has no plausible link to gastrin regulation. Nothing currently justifies moving forward.
To proceed, the following is needed:
- The FDA package insert warnings and contraindications, which are needed before any safety screening
- Confirmed mechanism of action data from DrugBank, and a written mechanistic hypothesis for gastrin regulation
- A systematic literature and trial registry search (PubMed, ClinicalTrials.gov, ICTRP) for any signal in this indication
- Route compatibility assessment (caspofungin is injectable only)
- Preclinical evidence, if a mechanistic hypothesis emerges, before reconsidering the decision
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.